Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
CTIX's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CTIX: No Debt )
CTIX' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: No Debt

Interest Coverage No Debt
CTIX's Interest Coverage is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CTIX: No Debt )
CTIX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: -2.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROA (%) -108.52
CTIX's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CTIX: -108.52 )
CTIX' s 10-Year ROA (%) Range
Min: -17478.57   Max: -108.52
Current: -108.52

-17478.57
-108.52
EBITDA Growth (%) -9.10
CTIX's EBITDA Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CTIX: -9.10 )
CTIX' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 81.7
Current: -9.1

0
81.7
» CTIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with CTIX



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 159.00
CTIX's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CTIX: 159.00 )
CTIX' s 10-Year P/B Range
Min: 0   Max: 193
Current: 159

0
193
EV-to-EBIT -55.12
CTIX's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CTIX: -55.12 )
CTIX' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -55.12

Valuation & Return

vs
industry
vs
history
Forward Rate of Return (Yacktman) 10.37
CTIX's Forward Rate of Return (Yacktman) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. CTIX: 10.37 )
CTIX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: 10.37

Business Description

Industry: »
Compare: » details
Cellceutix Corporation, formerly known as EconoShare was incorporated on August 1, 2005 in the State of Nevada and was organized for the purpose of developing a B2B website for an Asset Sharing market place and transaction system. On December 6, 2007, EconoShare, Inc. acquired Cellceutix Pharma, Inc., a privately owned Delaware corporation with Cellceutix Pharma becoming a wholly-owned subsidiary of EconoShare, Inc. As a result of the Exchange with Cellceutix Pharma, Inc., the Company has adopted the business plan of Cellceutix Pharma, Inc. and now is into an early stage developmental biopharmaceutical Company. It has acquired rights to seven (7) different pharmaceutical compound candidates that are designed for treatment of diseases which exist, or might exist in the future. The Company would initially spend most of its efforts and resources on its anti-cancer compound, Kevetrin(tm), for the treatment of certain cancers. This compound is furthest along in in-vivo studies in small animals. Based on the results, the Company has decided to advance Kevetrin along the regulatory and clinical pathway. The Company's current portfolio of product candidates in pre-clinical development includes: (i) two (2) anti-cancer agents targeting multiple tumors; (ii) one (1) candidate targeting psoriasis; (iii) one (1) candidate targeting rheumatoid arthritis; (iv) one (1) candidate with potential for indications of osteo-arthritis/asthma; (v) one (1) candidate with a potential for indications of neurological disorders for the treatment of Multiple Sclerosis, Lou Gehrig Disease, and/or Parkinson's Disease; and (vi) a small molecule with potential for development to treat hypertensive emergency. Its product candidate, Kevetrin. Kevetrin is initially being developed to treat certain cancers. The Company is in the business of developing innovative small molecule therapies to treat diseases with significant medical need, particularly in the areas of cancer and inflammatory disease. The Company's compounds are still in preclinical development. It competes with biopharmaceutical firms in the United States, Europe and elsewhere, as well as a growing number of large pharmaceutical companies that are applying biotechnology to its operations. In the United States, drugs are subject to rigorous regulation by the United States Food and Drug Administration ('FDA'). The Federal Food, Drug and Cosmetic Act, and other federal and state statutes and regulations, govern the testing, manufacture, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion of its products.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide